# Hill Physicians
*Your health. It's our mission.*

# Meaningful Use Stage I Checklist for Providers

This tool may be used by providers to determine which CQM measures they will report on. The workflow for each of the Core measures has been addressed in the Meaningful Use newsletters. The Practice action plan also provides suggestions on workflow changes and who should be responsible for capturing the data in the EHR. For instance, some measures may be entered by ancillary office staff.

## I - Must meet ALL 15 of the CORE Meaningful Use objectives

- [ ] Computerized physician order entry (CPOE) for >30% of unique patients with at least one medication in their medication list
- [ ] E-Prescribing (eRx) for > 40% of the permissible scripts for patients for whom the EHR was used
- [ ] Report ambulatory clinical quality measures to CMS/States on all your patients in the EHR
- [ ] Implement one clinical decision support rule
- [ ] Provide >50% patients seen with the EHR, an electronic copy of their health information within 3 business days, upon request
- [ ] Provide > 50% of patients seen with the EHR, a clinical summary within 3 business days
- [ ] Drug-drug and drug-allergy interaction checks turned on
- [ ] Record demographics as structured data on >50% of all patients seen: preferred language, gender, race, ethnicity, DOB
- [ ] Maintain an up-to-date problem list of current and active diagnoses on >80% of all patients seen at least one entry as structured data
- [ ] > 80% of all patients seen have at least one entry as structured data in the medication list
- [ ] > 80% of all patients seen have at least one entry as structured data in the medication allergy list
- [ ] > 50% of all patients age 2 and above seen with the EHR have vital signs (height, weight and blood pressure) recorded as structured data.
- [ ] Record >50% of patients smoking status for patients 13 years or older and seen with the EHR.
- [ ] Capability to exchange key clinical information among providers of care. Must perform at least one test of electronic data exchange of key clinical information.
- [ ] Ensure adequate privacy and security protections for personal health information. Conduct or review a security risk analysis and implement security updates as necessary and correct identified security deficiencies

## II - Must meet ANY 5 of the 10 Meaningful Use MENU SET Objectives listed below*

*At least 1 public health objective must be selected

- [ ] Implement drug -formulary checks with access to at least one internal or external drug formulary for the entire reporting period.
- [ ] > 40% of clinical lab test results are stored as structured data for patients seen with the EHR.
- [ ] Generate at least one report of patients by specific conditions to use for quality improvement, reduction of disparities, research or outreach.
- [ ] > 20% of all unique patients 65 years or older or 5 years old or younger seen with the EHR were sent an appropriate reminder per patient preference for preventive/follow up care
- [ ] > 10% of all patients seen are provided with timely electronic access (within four business days) to their health information.
- [ ] > 10% of all patients seen are provided patient-specific education resources through the use of certified EHR technology.
- [ ] Performs medication reconciliation on > 50% of transitions of care or relevant encounters for EHR patients.

- [ ] EP who transitions or refers the patient seen with the EHR to another setting of care will provide a summary of care record for > 50% of transitions and referrals.
- [ ] Perform at least one test of certified EHR technology's capability to submit electronic data to immunization registries/systems. *
- [ ] Perform at least one test of certified EHR technology's capability to provide electronic syndromic surveillance data to public health agencies. *

**Must track the 3 required CORE CLINICAL QUALITY MEASURES (CQM) below or the alternatives**

| Core Set : | Alternative Set: |
|---|---|
| [ ] Hypertension: blood pressure management | [ ] Weight Assessment and Counseling for Children and Adolescents |
| [ ] Tobacco use assessment and intervention | [ ] Influenza Immunization for Patients ≥ 50 Years Old |
| [ ] Adult weight screening and follow-up | [ ] Childhood Immunization Status |

**IV. Identify AT LEAST 3 additional CQM from the set of 38 CQMs that you commit to track on your patients**

| | Specialty | Measure |
|---|---|---|
| [ ] | P4P | Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus |
| [ ] | P4P | Diabetes: Low Density Lipoprotein (LDL) Management and Control |
| [ ] | P4P | Diabetes: Blood Pressure Management |
| [ ] | P4P | Diabetes: Eye Exam |
| [ ] | P4P | Diabetes: Urine Screening |
| [ ] | P4P | Diabetes: Foot Exam |
| [ ] | P4P | Diabetes: Hemoglobin A1c Control (<8.0) |
| [ ] | P4P | Controlling High Blood Pressure |
| [ ] | P4P | Use of Appropriate Medications for Asthma |
| [ ] | P4P | Appropriate Testing for Children with Pharyngitis |
| [ ] | P4P | Low Back Pain: Use of Imaging Studies |
| [ ] | P4P | Cervical Cancer Screening |
| [ ] | P4P | Chlamydia Screening for Women |
| [ ] | P4P | Breast Cancer Screening |
| [ ] | P4P | Colorectal Cancer Screening |

| | | |
|---|---|---|
| ☐ | Opth/DM | Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care |
| ☐ | Opth/DM | Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation |
| ☐ | Opth/DM | Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy |
| ☐ | ONC | Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer |
| ☐ | ONC | Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients |
| ☐ | ONC | Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients |
| ☐ | OB | Prenatal Care: Screening for Human Immunodeficiency Virus (HIV) |
| ☐ | OB | Prenatal Care: Anti-D Immune Globulin |
| ☐ | CARD | Heart Failure: ACE Inhibitor or ARB Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
| ☐ | CARD | Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) |
| ☐ | CARD | Coronary Artery Disease (CAD): Oral Anti-platelet Therapy Prescribed for Patients with CAD |
| ☐ | CARD | Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
| ☐ | CARD | Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol |
| ☐ | CARD | Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation |
| ☐ | CARD | Ischemic Vascular Disease (IVD): Blood Pressure Management |
| ☐ | CARD | Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic |
| ☐ | CARD | Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control |
| ☐ | | Asthma Pharmacologic Therapy |
| ☐ | | Asthma Assessment |
| ☐ | | Pneumonia Vaccination Status for Older Adults |
| ☐ | | Anti-depressant medication management: (a) Effective Acute Phase Treatment, (b) Effective Continuation Phase Treatment |
| ☐ | | Smoking and Tobacco Use Cessation, Medical assistance: Advising Smokers and Tobacco Users to Quit, Discussing Cessation Medications and Strategies |
| ☐ | | Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement |